Browse Category

EPA:OR News 8 December 2025 - 1 February 2026

Stock Market Today, December 8, 2025: Fed Rate-Cut Bets, China Trade Shock and a Gold–Stocks ‘Double Bubble’

Stock Market Today, December 8, 2025: Fed Rate-Cut Bets, China Trade Shock and a Gold–Stocks ‘Double Bubble’

Global stocks are starting the week in a holding pattern as traders brace for the year’s final Federal Reserve meeting, a wave of central‑bank decisions, fresh economic data, and heavyweight tech earnings. Under the surface, however, there’s plenty going on — from a surprise surge in Chinese exports to a rare warning that both gold and equities may be in bubble territory. Global markets today: cautious green with pockets of stress Equities are broadly flat to slightly higher, with “Fed week” keeping risk-taking in check: The S&P 500 itself is entering the week just below record levels — a little over 6,870

Stock Market Today

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

7 February 2026
Applied Digital Corporation shares jumped 25.52% Friday to $34.95, then slipped to $34.60 after hours. The company reported fiscal Q2 revenue up 250% to $126.6 million and signed leases for 600 MW of data center capacity in North Dakota. Applied Digital broke ground on a new 430‑MW campus in the southern U.S. in January. Financing includes a $100 million promissory note with 8% interest, paid in kind.
Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

7 February 2026
Eli Lilly shares rose 3.7% to $1,058.18 Friday after the FDA said it would act against telehealth firm Hims & Hers for marketing a $49 compounded weight-loss pill. The move followed a sharp selloff Thursday when Hims announced plans to sell a version of Novo Nordisk’s Wegovy. Investors remain uncertain how aggressively regulators will police copycat drugs and pricing in the obesity drug market.
Go toTop